Rezolute Inc. (6HV1)
FSX
Real-time Data
06:00 AM
Day's Range
3.5252 wk Range
1.01Overview - 6HV1 - Rezolute Inc.
Key Statistics
Valuation
Enterprise Value
221.16M
Price / Book
‪4.06‬
EV / EBITDA
‪-2.98‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-48.73%‬
Return on Equity
‪-81.72%‬
Ownership
Float
60.48M
Held by Insiders
‪10.15%‬
Held by Institutions
‪98.37%‬
Price stats
Beta
‪0.61‬
50-Day Avg
‪4.12‬
200-Day Avg
‪3.59‬
Peers - 6HV1 - Rezolute Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- 6HV1FSXRezolute Inc.-60.16%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0QFFSXModerna Inc.+83.96%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 3920FSXSpyre Therapeutics, Inc.+84.28%52-week change3.24P/E (Trailing)‪0.00%‬Profit Margin
- 5JA1FSXSprint Bioscience AB+85.38%52-week change3.38P/E (Trailing)‪54.44%‬Profit Margin
- 0GOFSXThalia Therapeutics Plc+87.50%52-week change-4.71P/E (Trailing)‪0.00%‬Profit Margin
- 6461FSX26 Metals Inc.+92.25%52-week change-0.34P/E (Trailing)‪0.00%‬Profit Margin
- 2CGFSXNanoSphere Health Sciences Inc.+93.33%52-week change0.05P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 6HV1 - Rezolute Inc.
About
Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
